Recent Updates
Recently added Catalysts

LY3873862

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: May 11, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05492201A Study of LY3873862 in Healthy ParticipantsPHASE1 COMPLETED 84 — — Aug 11, 2022Apr 29, 2025May 11, 20251 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through 72 days

A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Endpoints
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3873862
Predose up to 96 hours postdose
PK: Area Under the Concentration versus Time Curve at Steady State (AUCτ) of LY3873862
Predose up to 96 hours postdose
PK: Maximum Observed Concentration (Cmax) of LY3873862
Predose up to 96 hours postdose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
LY3873862 (Part A)EXPERIMENTALLY3873862 administered orally as single dose.
Placebo (Part A)PLACEBO_COMPARATORPlacebo administered orally.
LY3873862 (Part B)EXPERIMENTALLY3873862 administered orally as multiple doses.
Placebo (Part B)PLACEBO_COMPARATORPlacebo administered orally.
LY3873862 (Part C)EXPERIMENTALLY3873862 administered orally as multiple doses.
Placebo (Part C)PLACEBO_COMPARATORPlacebo administered orally.
Interventions
NameTypeDescription
LY3873862DRUGAdministered orally.
PlaceboDRUGAdministered orally.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²) * Are male or female participants, including those of childbearing potential Exclusion Criteria: * Have a histor...

Countries:United Kingdom
Unlock Eligibility Criteria